Karuna Therapeutics Inc

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Karuna Therapeutics reports positive trial results and strong financial outlook

Karuna Therapeutics is making significant progress in its key programs, with positive trial results and a focus on expanding its pipeline. Despite challenges in trial timelines and increased expenses, the company's strong financial position and strategic priorities position it well for future growth.

Karuna Therapeutics reports robust Q2 performance and eyes new indications

Karuna Therapeutics reported strong financials, progress on NDA submission, and ongoing Phase III programs.
The company's focus on cognitive benefits, broader efficacy, and potential new indications showcases strategic growth initiatives.
Challenges include competitive dynamics in Alzheimer's trials and uncertainties in the applicability of KarXT in certain patient populations.
Opportunities lie in exploring new indications, demonstrating cognitive benefits, and enhancing efficacy in mood and anxiety disorders.

Karuna Therapeutics excels in Q3, eyes global expansion for KarXT

Karuna Therapeutics demonstrated strong performance in Q3 with a focus on KarXT Phase III programs and NDA submission, supported by a healthy financial position.
Strategic strengths lie in maximizing KarXT value, positive payer interactions, and broad-based commercial strategies, while challenges include managing expenses and operational considerations.
Opportunities for growth include expanding the TRPC4/5 program, leveraging favorable mental health trends, and pursuing international market partnerships for KarXT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data

The biotech's psych med hit the mark in a late-stage trial.

Why Karuna Therapeutics Stock Is On Fire Today

Source: Bukhta Yurii / Shutterstock.com Karuna Therapeutics (NASDAQ: KRTX ) stock is rocketing higher on Monday thanks to results from its Phase 3 EMERGENT-2 trial. This trial covers the efficacy, safety, and tolerability of KarXT in adults suffering from schizophrenia.

Karuna Therapeutics (KRTX) Stock Soars 64% on Positive Clinical Data

Karuna Therapeutics topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high. The post Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win appeared first on Investor's Business Daily.

Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win

Shares of Karuna Therapeutics Inc. KRTX, +4.43% soared 42.6% in premarket trading on Monday after the company said its experimental treatment for schizophrenia met the primary endpoint in a Phase 3 clinical trial. Karuna told investors it expects to submit the therapy to the Food and Drug Administration in "mid-2023.

Karuna's stock jumps 42% after sharing promising Phase 3 data for its schizophrenia drug

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2022 and provided a general business update. In a separate press release issued today, the Company announced positive results from the Phase 3 EMERGENT-2 trial evaluating the efficacy, safety and tolerability of

Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The trial met its primary endpoint, with KarXT dem

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

SVB Leerink initiated coverage on Karuna Therapeutics Inc (NASDAQ: KRTX) with an Outperform rating and a price target of $170. SVB notes that Karuna already has one positive schizophrenia study (EMERGENT-1) with KarXT.

SVB Likes This 'Novel Antipsychotic'-Focused Stock

Fate Therapeutics

IVERIC bio Inc

Madrigal Pharmaceuticals

Nkarta, Inc.

Seagen

Takeda Pharmaceutical

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.

Trial Results Set to Make or Break Small-Cap Pharma Stocks

Treatments for schizophrenia – a truly complex disease--are plagued with a high late-stage trial failure rate. Phase 3 KarXT results will be released this quarter. It will be a binary event.

Karuna Therapeutics: Front-Running KarXT Phase 3

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Karuna Therapeutics, Inc. ("Karuna" or "the Company") (NASDAQ: KRTX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm

Alnylam Pharmaceuticals

Baxter

Biogen

Boston Scientific

Cardinal Health

Gilead Sciences

Johnson & Johnson

Medtronic

Mirati Therapeutics

Natera

Roche Holding AG

Stryker

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m. ET. The one-hour webcast event will highlight progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating Kar

Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer's Disease

Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.

Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the first quarter of 2022 and provided a general business update. “We have made significant progress advancing our comprehensive late-stage clinical programs for KarXT, most notably with the completion of enrollment of our registrati

Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 8:00 a.m. ET. A live webcast of the presentation will be availabl

Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference

According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia.  The Company had expected topline data from the EMERGENT-3 trial in 2H of 2022.

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a general business update. “We are excited by the momentum we've built in executing our comprehensive late-stage clinical program for KarXT this past year, which

Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update

Let's take a deeper dive into Karuna Therapeutics Inc. ( KRTX , Financial), which was one of the potential takeover targets I discussed last week.

Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 10:00 a.m. ET. A live webcast of the presentation will be available on the Investor Relations page of Karuna's website at

Karuna Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

In the premium service, we had over a 3x gain in the stock after a Phase 2 trial data to treat acute psychosis in known schizophrenia. Data from the first Phase 3 trial in this indication is expected in mid-2022.

Karuna Therapeutics: Starting A Position With 50% Short-Term Upside Potential

Intercept Pharma

This could be a very exciting year for these drugmakers.

3 Can't-Miss Biotech Events Coming Up in 2022

Apellis Pharma

Arvinas Inc

Axsome Therapeutics

Coursera

Global Blood Therapeutics

Sunnova Energy International Inc

PDC Energy Inc

Rocket Pharma

Tenable Holdings Inc

Varonis Systems

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

12 Super Small-Cap Stocks to Buy for 2022 and Beyond

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairman, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 a.m. ET. A live webcast of the presentation will be available on the Investor Re

Karuna Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Charmaine Lykins as chief commercial officer, effective November 29, 2021. “We are pleased to welcome Charmaine to our leadership team at this pivotal time for Karuna,” said Steve Paul, M.D., chief executive officer, president, and chai

Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer

News for Karuna Therapeutics Inc Stock (KRTX)